Read Time: 4 mins

ADA–EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes in an Afro-Asian Context: Broadening the Perspective

Copy Link
Published Online: Apr 25th 2023 touchREVIEWS in Endocrinology. 2023;19(2):4-6 DOI:
Authors: Saptarshi Bhattacharya, Sanjay Kalra
Quick Links:
Article Information

The American Diabetes Association and the European Association for the Study of Diabetes consensus statement 2022 effectively captures the changing paradigm of modern diabetes care. As emphasized in the guidelines, a person-centered decision cycle focusing on preventing complications and improving quality of life is the driving principle behind modern diabetes management. Other notable features of the document are its emphasis on self-management education, therapeutic behaviour, sleep hygiene, nonalcoholic fatty liver disease and weight loss. Focus on individualization of care, social determinants of health, and ethnic variations are pertinent from an Afro-Asian perspective. The language matters section is a welcome addition that will help to overcome several barriers in diabetes care.


Africa, Asia, diabetes complications, diabetes mellitus, person-centered care, self-management of diabetes, social determinants of health


The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) consensus statement 2022 is a valuable addition that will help streamline type 2 diabetes mellitus management.1 The focus on individualized and person-centric care in the statement is welcome. The draft also acknowledges the significance of language, as it plays a decisive role in enhancing motivation and improving compliance.2 Promoting self-management education and encouraging self-care are obligatory in chronic conditions such as diabetes. Appropriate therapeutic behaviour will not only optimize the individual outcome, but the active involvement of all stakeholders is required to overcome the challenge of the rising burden of the disease. An important incorporation from a global perspective is the section on nonalcoholic fatty liver disease, given its rising prevalence worldwide. The guidelines emphasize the necessity for a holistic approach, though, from an Afro-Asian perspective, a few additional facets need to be highlighted.

Weight optimization in the Afro-Asian context

As per the International Diabetes Federation estimates, of the 536.6 million people with diabetes, 393.0 million reside in the Western Pacific, Southeast Asia, the Middle East and Africa.3 Therefore, almost two-thirds of the global population with diabetes are from Asia and Africa. The population of these two vast continents is heterogeneous. Though obesity is the principal driver of the diabetes epidemic in Africa, in Asia, people are predisposed to develop metabolic and cardiovascular disease (CVD) despite a low body mass index.4,5 The CVD prevalence in both continents is on the rise, often occurring prematurely, with diabetes and obesity implicated as major contributory factors.6,7

Thin fat obesity, often considered the tropical phenotype of obesity, has been attributed to increased visceral adiposity.810 Weight loss interventions are still effective in modifying the course of diabetes in most Afro-Asians; however, many Asians are already underweight and may benefit from a different therapeutic strategy.11 From an Afro-Asian context, given the heterogeneity in phenotype, the focus should be on weight optimization, whilst most Western guidelines, including the ADAEASD statement, stress the need for weight loss only.

The choice of glucose-lowering agent

Most recent guidelines recommend glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium–glucose cotransporter-2 inhibitors for individuals with diabetes and comorbid atherosclerotic CVDheart failure or diabetic kidney disease, based on positive results from several cardiovascular outcome trials.1,12 Meta-analyses of these trials suggest that Asians may benefit more from these drugs.13,14

However, the high cost of these agents, especially GLP-1 RA, often restricts their widespread use in developing countries. Tirzepatide, a recently approved dual glucose-dependent insulinotropic polypeptide and GLP-1 RA, has even less relevance in the Afro-Asian context due to its cost and lack of availability.15 Furthermore, as discussed, lean and underweight individuals comprise a significant proportion of people with diabetes in Asia who do not favour additional weight loss. The clinician has to balance the cardiovascular and renal benefits of these medicines against the risk of excessive weight loss.

In most Western guidelines, sulphonylureas are a third or fourth option glucose-lowering drug as they cause hypoglycaemia and weight gain, and their cardiovascular safety is equivocal.1,12 However, they continue to be a popular choice in developing countries. They are affordable, easily available and exert a potent glucose-lowering effect. Asian guidelines continue to advocate using sulphonylureaswhich may be especially useful for those who are underweight.16,17 Moreover, the cost-effectiveness of metformin and sulphonylurea combination has been demonstrated in several studies.1821

A recent meta-analysis found that weight loss of >10% increased the risk of mortality and CVD in type 2 diabetes mellitus.22 A long-term follow-up study in an Iranian population suggested that >5% weight gain improved CVD outcomes in the elderly and the impact of sulphonylurea-induced weight gain was not unfavourable.23 These findings raise the possibility that the beneficial response to glucose-lowering drugs can vary according to ethnicity and calls for focused studies to answer these questions.

Comorbidities beyond macro- and microvascular complications

For most developed countries, cardiovascular, renal and hepatic diseases account for the major burden of mortality and morbidity associated with diabetes.24,25 The ADAEASD statement rightfully emphasizes strategies to prevent and treat these complications. Besides the high affliction rate with chronic metabolic comorbidities, problems such as acute infections pose a significant challenge in developing countries.26 Diabetes can worsen several Afro-Asian endemic infections such as tuberculosis, melioidosis and dengue.27 Intensive glycaemic control is required for the early resolution of these diseases. Highlighting the need for a dedicated approach to infection-related complications of diabetes in the Afro-Asian context could be beneficial.

Healthcare delivery and social determinants of health

The loco-national health delivery system and social risk factors for inequitable care are often the critical determinants of the treatment strategy. The recent ADAEASD statement aptly highlights that. In Afro-Asian countries, the healthcare systems vary widely between countries and often within a country.2831 Access to insurance or state-sponsored medical facility may not be universally available. Not uncommonly, the cost of therapy for diabetes has to be borne by the patient and their family and may interfere with the therapeutic choice. Even then, when used timely and judiciously, inexpensive medicines such as sulphonylureas, metformin and non-analogue insulins have proven long-term efficacy in preventing micro- and macrovascular complications. These benefits continue for decades as evident from the The UK Prospective Diabetes Study.32

A holistic perspective on health

Whilst the focus on a holistic approach to managing diabetes is heartening, there is a lack of discussion regarding yoga, integrative medicine and spiritual health. All of these are important in East Asian societies and also assume significance from a global standpoint. The burden of diabetes requires integrating different schools of medicine and thought processes to tackle it. The benefits of yoga are backed by evidence and finds its role as an adjuvant therapy for diabetes.33 Furthermore, the role of integrative medicine in targeting diabetes cannot be underplayed.34 Emerging evidence suggests that meditation, spiritual belief and faith-based interventions, fitness qigong and tai chi, art therapy, acupressure, and natural medicines positively impact glycaemic control.35–40 More information from well-conducted randomized controlled trials can pave the way for integrating these non-conventional methods into mainstream therapy.


Most recommendations in the recent ADAEASD statement are helpful in the Afro-Asian context. In contemporary diabetes management, the therapeutic plan is individualized depending on medical, behavioural, psychological and social factors. A holistic approach to diabetes care, where the different dimensions of health are being addressed, will broaden the global perspective of the guideline.

Article Information:

Saptarshi Bhattacharya and Sanjay Kalra have no financial or non-financial relationships or activities to declare in relation to this article.

Compliance With Ethics

This article is an opinion piece and does not report on new clinical data, or any studies with human or animal subjects performed by any of the authors.

Review Process

Double-blind peer review.


The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.


Sanjay Kalra, Department of Endocrinology, Bharti Hospital, Karnal, 132001, India. E: brideknl@ gmail. com


No funding was received in the publication of this article.


This article is freely accessible at © Touch Medical Media 2023

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the writing of this article.




1. Davies MJAroda VRCollins BSet alManagement of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association(ADA) and the European association for the study of diabetes (EASD). Diabetes Care2022;45:275386. DOI10.2337/dci22-0034

2. Peimani MNasli-Esfahani ESadeghi RPatients’ perceptions of patient-provider communication and diabetes care: A systematic review of quantitative and qualitative studiesChronic Illn. 2020;16:3–22. DOI10.1177/1742395318782378

3. Sun HSaeedi PKaruranga Set alIDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045Diabetes Res Clin Pract. 2022;183:109119. DOI10.1016/j.diabres.2021.109119

4. Gujral UPPradeepa RWeber MBet alType 2 diabetes in South Asians: Similarities and differences with white Caucasian and other populationsAnn N Y Acad Sci. 2013;1281:5163. DOI10.1111/j.1749-6632.2012.06838.x

5. Chan JCNMalik VJia Wet alDiabetes in Asia: Epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:212940. DOI10.1001/jama.2009.726

6. Zhao DEpidemiological features of cardiovascular disease in Asia. JACC Asia. 2021;1:1–13. DOI10.1016/j.jacasi.2021.04.007

7. Minja NWNakagaayi DAliku Tet alCardiovascular diseases in Africa in the twenty-first century: Gaps and priorities going forwardFront Cardiovasc Med. 2022;9:1008335. DOI: 10.3389/fcvm.2022.1008335

8. Cao CHu HZheng Xet alAssociation between central obesity and incident diabetes mellitus among Japanese: A retrospective cohort study using propensity score matching. Sci Rep. 2022;12:13445. DOI10.1038/s41598-022-17837-1

9. Indulekha KAnjana RMSurendar JMohan V. Association of visceral and subcutaneous fat with glucose intolerance, insulin resistance, adipocytokines and inflammatory markers in Asian Indians (CURES-113). Clin Biochem. 2011;44:2817. DOI10.1016/j.clinbiochem.2010.12.015

10. Kapoor NThin fat obesity: The tropical phenotype of obesityInFeingold KRAnawalt BBoyce A, (eds)., Inc2000Available at: (accessed date12 January 2023)

11. Sattar NWelsh PLeslie WSet alDietary weight-management for type 2 diabetes remissions in South Asians: The South Asian diabetes remission randomised trial for proof-of-concept and feasibility (STANDby)Lancet Reg Health Southeast Asia. 2023;9:100111. DOI10.1016/j.lansea.2022.100111

12. Blonde LUmpierrez GEReddy SSet alAmerican association of clinical endocrinology clinical practice guideline: Developing a diabetes mellitus comprehensive care plan-2022 updateEndocr Pract. 2022;28:9231049. DOI10.1016/j.eprac.2022.08.002

13. Lee MMYGhouri NMcGuire DKet alMeta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2is and GLP-1RAs in Asian versus white patients with and without type 2 diabetes. Diabetes Care. 2021;44:123641. DOI10.2337/dc20-3007

14. Diallo ACarlos-Bolumbu MGaltier FAge, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis. EClinicalMedicine. 2022;54:101697. DOI10.1016/j.eclinm.2022.101697

15. Frías JPDavies MJRosenstock Jet alTirzepatide versus semaglutide once weekly in patients with type 2 diabetesN Engl J Med2021;385:50315. DOI10.1056/NEJMoa2107519

16. Kalra SBahendeka SSahay Ret alConsensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus – International task forceIndian J Endocrinol Metab. 2018;22:13257. DOI10.4103/ijem.IJEM_556_17

17. Lim L-LLau ESHCheung JTKet alReal-world usage of sulphonylureas in Asian patients with type 2 diabetes using the joint Asia diabetes evaluation (JADE) registerDiabetes Obes Metab2023;25:20821DOI10.1111/dom.14865

18. Gu SShi LShao Het alChoice across 10 pharmacologic combination strategies for type 2 diabetes: A cost-effectiveness analysisBMC Med. 2020;18:378. DOI10.1186/s12916-020-01837-x

19. Chien CLChen YCMalone DCet alCost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metforminCurr Med Res Opin2020;36:161926. DOI: 10.1080/03007995.2020.1815686

20. Permsuwan UDilokthornsakul PThavorn Ket alCost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in ThailandJ Med Econ. 2017;20:17181. DOI10.1080/13696998.2016.1238386

21. Nguyen-Thi HYNguyen NTLe NDTet alCost-effectiveness of gliclazide-based intensive glucose control vs. standard glucose control in type 2 diabetes mellitus. An economic analysis of the advance trial in VietnamFront Public Health. 2020;8:562023. DOI10.3389/fpubh.2020.562023

22. Huang SShi KRen Yet alAssociation of magnitude of weight loss and weight variability with mortality and major cardiovascular events among individuals with type 2 diabetes mellitus: A systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21:78. DOI10.1186/s12933-022-01503-x

23. Moazzeni SSHizomi Arani RDeravi Net alWeight change and risk of cardiovascular disease among adults with type 2 diabetes: More than 14 years of follow-up in the Tehran lipid and glucose studyCardiovasc Diabetol. 2021;20:141. DOI10.1186/s12933-021-01326-2

24. Einarson TRAcs ALudwig CPanton UHPrevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007-2017Cardiovasc Diabetol. 2018;17:83. DOI10.1186/s12933-018-0728-6

25. Gheith OFarouk NNampoory Net alDiabetic kidney disease: World wide difference of prevalence and risk factorsJ Nephropharmacol2016;5:4956.

26. Dunachie SChamnan PThe double burden of diabetes and global infection in low and middle-income countriesTrans R Soc Trop Med Hyg2019;113:5664DOI10.1093/trstmh/try124

27. van Crevel Rvan de Vijver SMoore DAJThe global diabetes epidemic: What does it mean for infectious diseases in tropical countries? Lancet Diabetes Endocrinol. 2017;5:45768. DOI10.1016/S2213-8587(16)30081-X

28. Jiang WXu XTang Set alInequity in healthcare needs, health service use and financial burden of medical expenditures in China: Results from a consecutive household monitoring study in Jiangsu ProvinceBMC Health Serv Res2019;19:966DOI10.1186/s12913-019-4796-4

29. Carapinha JLRoss-Degnan D, Desta ATWagner AK. Health insurance systems in five sub-Saharan African countries: Medicine benefits and data for decision making. Health Policy. 2011;99:193202. DOI10.1016/j.healthpol.2010.11.009

30. Du WLiu PXu WEffects of decreasing the out-of-pocket expenses for outpatient care on health-seeking behaviors, health outcomes and medical expenses of people with diabetes: Evidence from ChinaInt J Equity Health. 2022;21:162. DOI10.1186/s12939-022-01775-5

31. Moucheraud CLenz CLatkovic MWirtz VJThe costs of diabetes treatment in low- and middle-income countries: A systematic reviewBMJ Glob Health. 2019;4:e001258. DOI10.1136/bmjgh-2018-001258

32. Holman RRPaul SKBethel MAet al10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med2008;359:157789DOI10.1056/NEJMoa0806470

33. Dutta DBhattacharya SSharma Met alEffect of yoga on glycemia and lipid parameters in type-2 diabetes: A meta-analysisJ Diabetes Metab Disord2021;20:34967. DOI10.1007/s40200-021-00751-0

34. Redmer JLongmier EWedel PTargeting diabetes: The benefits of an integrative approachJ Fam Pract. 2013;62:33744.

35. Priya GKalra SMind-body interactions and mindfulness meditation in diabetesEur Endocrinol2018;14:3541. DOI10.17925/EE.2018.14.1.35

36. Onyishi CNIlechukwu LCVictor-Aigbodion VEseadi C. Impact of spiritual beliefs and faith-based interventions on diabetes managementWorld J Diabetes2021;12:63041. DOI10.4239/wjd.v12.i5.630

37. Li XSi HChen Yet alEffects of fitness qigong and tai chi on middle-aged and elderly patients with type 2 diabetes mellitusPLoS One. 2020;15:e0243989. DOI10.1371/journal.pone.0243989

38. Yang QShao QXu Qet alArt therapy alleviates the levels of depression and blood glucose in diabetic patients: A systematic review and meta-analysisFront Psychol. 2021;12:639626. DOI10.3389/fpsyg.2021.639626

39. Salmani Mood MYavari ZBahrami Taghanaki H, Mahmoudirad G. The effect of acupressure on fasting blood glucose, glycosylated hemoglobin and stress in patients with type 2 diabetesComplement Ther Clin Pract. 2021;43:101393. DOI10.1016/j.ctcp.2021.101393

40. Setiyorini EQomaruddin MBWibisono Set alComplementary and alternative medicine for glycemic control of diabetes mellitus: A systematic reviewJ Public Health Res. 2022;11:22799036221106582. DOI10.1177/22799036221106582

Further Resources

Share this Article
Related Content In Diabetes
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72